EurekAlert!4 年
PD-1/PD-L1抑制剂治疗肺癌的前景与挑战
目前美国FDA已批准Nivolumab、Pembrolizumab（PD-1抑制剂）、Atezolizumab、Avelumab和Durvalumab（PD-L1抑制剂）应用于肿瘤的临床治疗。然而，哪些患者受益最多 ...
纳武单抗(Opdivo)联合伊匹单抗(Yervoy) 一线治疗NSCLC获EC批准
百时美施贵宝（BMS）向外公布欧盟委员会（EC）现已批准纳武单抗 (Opdivo，nivolumab)和伊匹单抗 (Yervoy，ipilimumab) ...
来自MSN2 年
免疫治疗到底能不能延长患者生命？
目前已经有3个免疫检查点抑制剂（PD-1抑制剂Nivolumab，PD-1抑制剂pembrolizumab，和PD-L1抑制剂Atezolizumab）被批准上市用于治疗肺癌，而且还有上百个各种 ...
Targeted Oncology7 天
HBI-8000 Plus Nivolumab Is Safe, Active in Melanoma
The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no ...
ascopubs.org27 天
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients ...
The authors acknowledge Ono Pharmaceutical Company, Ltd (Osaka, Japan) for contributions to nivolumab development and Dako, an Agilent Technologies, Inc company (Santa Clara, CA) for collaborative ...
Cure Today13 天
PD-L1, KIM-1 Levels May Predict Kidney Cancer Response to Opdivo, Yervoy
PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels ...
EurekAlert!1 个月
Nature Communications: Nivolumab and anlotinib show promising results in advanced stomach ...
Nivolumab is an immunotherapy that helps the ... Researchers also made a promising discovery: the association of CD68+ PD-L1+ PD-1+ macrophages with improved survival, positing these macrophages ...
The American Journal of Managed Care1 天
Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC
Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following ...